JP2012519207A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012519207A5 JP2012519207A5 JP2011552515A JP2011552515A JP2012519207A5 JP 2012519207 A5 JP2012519207 A5 JP 2012519207A5 JP 2011552515 A JP2011552515 A JP 2011552515A JP 2011552515 A JP2011552515 A JP 2011552515A JP 2012519207 A5 JP2012519207 A5 JP 2012519207A5
- Authority
- JP
- Japan
- Prior art keywords
- lenalidomide
- nitro
- solvent system
- piperidine
- alcohol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN383/KOL/2009 | 2009-03-02 | ||
| IN383KO2009 | 2009-03-02 | ||
| IN463KO2009 | 2009-03-16 | ||
| IN463/KOL/2009 | 2009-03-16 | ||
| PCT/GB2010/050352 WO2010100476A2 (en) | 2009-03-02 | 2010-03-01 | Improved process |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012519207A JP2012519207A (ja) | 2012-08-23 |
| JP2012519207A5 true JP2012519207A5 (enExample) | 2013-04-18 |
| JP5727944B2 JP5727944B2 (ja) | 2015-06-03 |
Family
ID=54290149
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011552515A Expired - Fee Related JP5727944B2 (ja) | 2009-03-02 | 2010-03-01 | 改良プロセス |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US8946265B2 (enExample) |
| EP (1) | EP2403845B1 (enExample) |
| JP (1) | JP5727944B2 (enExample) |
| CN (1) | CN102414196A (enExample) |
| AU (1) | AU2010220204B2 (enExample) |
| CA (1) | CA2753241C (enExample) |
| CY (1) | CY1115376T1 (enExample) |
| DK (1) | DK2403845T3 (enExample) |
| ES (1) | ES2487215T3 (enExample) |
| HR (1) | HRP20140686T1 (enExample) |
| NZ (1) | NZ595492A (enExample) |
| PL (1) | PL2403845T3 (enExample) |
| PT (1) | PT2403845E (enExample) |
| SI (1) | SI2403845T1 (enExample) |
| SM (1) | SMT201400100B (enExample) |
| WO (1) | WO2010100476A2 (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA83504C2 (en) | 2003-09-04 | 2008-07-25 | Селджин Корпорейшн | Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione |
| TWI475014B (zh) * | 2009-09-17 | 2015-03-01 | Scinopharm Taiwan Ltd | 固體形態的３－（４－胺基－１－側氧基－１，３－二氫－異吲哚－２－基）－哌啶－２，６－二酮及其製造方法 |
| WO2011064574A1 (en) | 2009-11-24 | 2011-06-03 | Generics [Uk] Limited | Hplc method for detecting lenalidomide |
| KR20130038232A (ko) | 2010-03-08 | 2013-04-17 | 낫코 파마 리미티드 | 무수 레날리도마이드 ｆｏｒｍ-ｉ |
| US9044479B2 (en) | 2010-06-16 | 2015-06-02 | Bruce Chandler May | Use of levocetirizine and montelukast in the treatment of influenza, common cold and inflammation |
| WO2013005229A1 (en) * | 2011-07-05 | 2013-01-10 | Hetero Research Foundation | Process for lenalidomide |
| CA2842316A1 (en) | 2011-07-19 | 2013-01-24 | Amplio Pharma, Llc | Urea cocrystal of 3-(4-amin0-1-0x0-1,3 dihydro-isoindol-2-yl)piperidine-2,6-dione |
| CN102838586A (zh) * | 2012-09-20 | 2012-12-26 | 重庆泰濠制药有限公司 | 一种制备来那度胺的方法 |
| AU2014249531B2 (en) | 2013-03-13 | 2018-11-29 | IRR, Inc. | Use of levocetirizine and montelukast in the treatment of traumatic injury |
| JP2016512262A (ja) | 2013-03-13 | 2016-04-25 | インフラマトリー・レスポンス・リサーチ・インコーポレイテッド | 血管炎の処置におけるレボセチリジン及びモンテルカストの使用 |
| ES2745041T3 (es) * | 2013-03-13 | 2020-02-27 | Inflammatory Response Res Inc | Uso de levocetirizina y montelukast en el tratamiento de trastornos autoinmunitarios |
| WO2014160686A1 (en) * | 2013-03-26 | 2014-10-02 | Celgene Corporation | Solid forms comprising 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione and a coformer, compositions and methods of use thereof |
| CN103601717A (zh) * | 2013-10-09 | 2014-02-26 | 湖南华腾制药有限公司 | 一种来那度胺的新型制备方法 |
| LV14985B (lv) | 2013-10-14 | 2015-06-20 | Latvijas Organiskās Sintēzes Institūts | Lenalidomīda iegūšanas process |
| WO2014155371A2 (en) * | 2014-04-26 | 2014-10-02 | Shilpa Medicare Limited | Crystalline lenalidomide process |
| WO2016024286A2 (en) * | 2014-08-11 | 2016-02-18 | Avra Laboratories Pvt. Ltd. | An improved process for synthesis of lenalidomide |
| EP3183244B1 (en) * | 2014-08-19 | 2019-04-10 | Synthon BV | Process for making crystalline form a of lenalidomide |
| JP2017526728A (ja) | 2014-09-15 | 2017-09-14 | インフラマトリー・レスポンス・リサーチ・インコーポレイテッド | 炎症介在性状態の治療におけるレボセチリジン及びモンテルカスト |
| WO2017109041A1 (en) * | 2015-12-22 | 2017-06-29 | Synthon B.V. | Pharmaceutical composition comprising amorphous lenalidomide and an antioxidant |
| US10899793B2 (en) | 2016-05-27 | 2021-01-26 | Regents Of The University Of Minnesota | Melanocortin ligands and methods of use thereof |
| US11124541B2 (en) | 2016-10-18 | 2021-09-21 | Regents Of The University Of Minnesota | Chimeric melanocortin ligands and methods of use thereof |
| EP3687987A4 (en) * | 2017-09-27 | 2021-03-24 | Biocon Limited | CRYSTALLINE FORMS OF LENALIDOMIDE |
| WO2019138424A1 (en) * | 2018-01-11 | 2019-07-18 | Natco Pharma Limited | Stable pharmaceutical compositions comprising lenalidomide |
| US11332499B2 (en) | 2018-08-16 | 2022-05-17 | Regents Of The University Of Minnesota | Cyclic peptides and methods of use thereof |
| CN111196800B (zh) * | 2018-11-19 | 2022-10-11 | 欣凯医药化工中间体（上海）有限公司 | 一种制备来那度胺的方法 |
| WO2021236518A1 (en) | 2020-05-19 | 2021-11-25 | IRR, Inc. | Levocetirizine and montelukast in the treatment of sepsis and symptoms thereof |
| WO2022144924A1 (en) * | 2021-01-04 | 2022-07-07 | Avra Laboratories Pvt. Ltd. | An improved process for synthesis of lenalidomide |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5635517B1 (en) | 1996-07-24 | 1999-06-29 | Celgene Corp | Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines |
| US6281230B1 (en) | 1996-07-24 | 2001-08-28 | Celgene Corporation | Isoindolines, method of use, and pharmaceutical compositions |
| UA83504C2 (en) | 2003-09-04 | 2008-07-25 | Селджин Корпорейшн | Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione |
| ES2437592T3 (es) * | 2004-09-03 | 2014-01-13 | Celgene Corporation | Procedimientos para la preparación de 2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolinas sustituidas |
| US8304250B2 (en) | 2007-04-16 | 2012-11-06 | Momenta Pharmaceuticals, Inc. | Multi-dimensional chromatographic methods for separating N-glycans |
| US20110041589A1 (en) | 2007-12-14 | 2011-02-24 | Generics [Uk] Limited | New hpcl method |
| WO2009114601A2 (en) | 2008-03-11 | 2009-09-17 | Dr. Reddy's Laboratories Ltd. | Preparation of lenalidomide |
| EP2364305A1 (en) | 2008-11-03 | 2011-09-14 | Generics (UK) Limited | A crystalline form of lenalidomide and a process for its preparation |
| WO2011064574A1 (en) | 2009-11-24 | 2011-06-03 | Generics [Uk] Limited | Hplc method for detecting lenalidomide |
-
2010
- 2010-03-01 PT PT107079501T patent/PT2403845E/pt unknown
- 2010-03-01 US US13/254,249 patent/US8946265B2/en active Active
- 2010-03-01 HR HRP20140686AT patent/HRP20140686T1/hr unknown
- 2010-03-01 DK DK10707950.1T patent/DK2403845T3/da active
- 2010-03-01 WO PCT/GB2010/050352 patent/WO2010100476A2/en not_active Ceased
- 2010-03-01 EP EP10707950.1A patent/EP2403845B1/en active Active
- 2010-03-01 NZ NZ595492A patent/NZ595492A/xx not_active IP Right Cessation
- 2010-03-01 PL PL10707950T patent/PL2403845T3/pl unknown
- 2010-03-01 AU AU2010220204A patent/AU2010220204B2/en not_active Ceased
- 2010-03-01 CA CA2753241A patent/CA2753241C/en active Active
- 2010-03-01 ES ES10707950.1T patent/ES2487215T3/es active Active
- 2010-03-01 CN CN2010800195527A patent/CN102414196A/zh active Pending
- 2010-03-01 SI SI201030679T patent/SI2403845T1/sl unknown
- 2010-03-01 JP JP2011552515A patent/JP5727944B2/ja not_active Expired - Fee Related
-
2014
- 2014-07-24 CY CY20141100562T patent/CY1115376T1/el unknown
- 2014-07-28 SM SM201400100T patent/SMT201400100B/xx unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012519207A5 (enExample) | ||
| CN101253163B (zh) | 4-氨基-2-(2,6-二氧哌啶-3-基)异吲哚啉-1,3-二酮化合物的制备方法 | |
| JP5426693B2 (ja) | アゴメラチンハロゲン化水素複合体及びその製造方法 | |
| ES3024232T3 (en) | Fenfluramine compositions and methods of preparing the same | |
| US20100016590A1 (en) | Nilotinib intermediates and preparation thereof | |
| KR101472686B1 (ko) | 벤즈이미다졸 유도체의 제조방법 | |
| JP2016512824A5 (enExample) | ||
| CN102414196A (zh) | 改进的方法 | |
| JP5373996B2 (ja) | サクサグリプチン中間体、サクサグリプチン多形及びそれらの調製方法 | |
| WO2015163447A1 (ja) | ４環性化合物の新規結晶 | |
| JP2014208718A (ja) | スコピンエステルを調製するための新規プロセス | |
| CN110891947B (zh) | 制备艾乐替尼或其药学上可接受的盐的方法 | |
| US10392364B2 (en) | Process for synthesis of lenalidomide | |
| CN111315722B (zh) | 制备月桂酰阿立哌唑的方法 | |
| US20160355533A1 (en) | Crystalline Fosaprepitant Dicyclohexylamine Salt And Its Preparation | |
| JP2022060192A5 (enExample) | ||
| KR101032600B1 (ko) | 고순도 레바미피드의 제조방법 | |
| WO2020053795A2 (en) | Process for the preparation of acalabrutinib and its intermediates | |
| WO2014188445A1 (en) | PROCESS FOR THE PREPARATION OF (3β)-17-(3-PYRIDINYL)ANDROSTA-5,16-DIEN-3-YL ACETATE AND POLYMORPH THEREOF | |
| EP3679030B1 (en) | A process for preparation of triaminopyrimidine compound and intermediates thereof | |
| CN105884673B (zh) | 一种吲哚衍生物的合成方法 | |
| CN101029045A (zh) | 一种制备4－(3－吡啶基)－1h－咪唑－1－丁胺的方法 | |
| CN103298795A (zh) | 用于制备来曲唑的纯中间体 | |
| CN106279112A (zh) | 一种克里唑替尼中间体及其制备方法和应用 | |
| CN111808172B (zh) | 肺念菌素b0衍生物及其制备方法和用途 |